Annexon Inc. is a clinical-stage biotechnology company dedicated to developing treatments that target the complement system, a key component of the immune response implicated in a range of neurodegenerative and neuroinflammatory disorders. The company’s lead assets are monoclonal antibodies designed to inhibit specific complement proteins, with the goal of preventing or mitigating tissue damage caused by aberrant complement activation. Annexon’s research focuses on conditions such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, amyotrophic lateral sclerosis and Parkinson’s disease.
The company’s pipeline is anchored by ANX005, an antibody that binds to C1q and blocks activation of the classical complement cascade. ANX005 has completed Phase 2 studies in neuromuscular indications and is being explored in additional neurodegenerative settings. Annexon’s second clinical candidate, ANX007, inhibits C1q-mediated synapse loss, and is currently under investigation for diseases characterized by synaptic dysfunction. Together, these programs represent a differentiated approach to modulating complement biology in both peripheral and central nervous system disorders.
Founded in 2015 by a team of scientists and executives with deep expertise in immunology and neuroscience, Annexon is headquartered in South San Francisco. The company was built on foundational research linking complement activation to neuronal injury, and it has since forged collaborations with leading academic and industry partners to support its drug development strategy. Leadership is led by President and Chief Executive Officer Brett Monia, Ph.D., whose prior experience includes senior roles at Ionis Pharmaceuticals and Alnylam, and Chief Scientific Officer Kirlos Dhillon, M.D., who has overseen early-stage research in complement-targeted therapies.
Annexon conducts its clinical trials across North America and Europe, engaging with investigational sites and regulatory authorities in multiple regions. The company’s integrated approach combines in-house research capabilities with external collaborations and licensing agreements to advance its complement inhibition platform. As Annexon advances its programs through clinical development, it aims to address significant unmet medical needs in neurological diseases driven by dysregulated complement activity.
AI Generated. May Contain Errors.
